scholarly journals Role of chemotherapy for early stage carcinoma of the ampulla of vater treated by pancreaticoduodenectomy – a single centre series

HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e406
Author(s):  
L. Varatharajan ◽  
M.H. Sodergren ◽  
N. Tapuria ◽  
A. Wotherspoon ◽  
J. Thompson ◽  
...  
Keyword(s):  
Early Stage ◽  
Ampulla Of Vater ◽  
Single Centre ◽  
Early Stage Carcinoma

Oesophageal cancer

2016 ◽  
pp. 365-387
Author(s):  
Piet Dirix ◽  
Karin Haustermans ◽  
Eric Van Cutsem ◽  
Xavier Sagaert ◽  
Christophe M. Deroose ◽  
...  
Keyword(s):  
Oesophageal Cancer ◽  
Palliative Treatment ◽  
Early Stage ◽  
Locally Advanced ◽  
Adjuvant Chemoradiotherapy ◽  
Locally Advanced Tumors ◽  
Early Stage Carcinoma ◽  
Advanced Tumors

Worldwide, oesophageal cancer, including cancer of the gastro-oesophageal junction (GEJ), is the sixth leading cause of death from cancer. Despite recent advances, treatment of oesophageal cancer remains challenging and is best approached by an experienced multidisciplinary team. Surgery alone is the treatment of choice in early stage carcinoma although in superficial cancers (T1a) endoscopic resection is to be preferred. In locally advanced tumors induction therapy followed by surgery is the preferred treatment. In selected cases definitive chemoradiotherapy could be considered as a valuable alternative The role of adjuvant chemotherapy is unclear, but could be considered for selected GEJ adenocarcinoma patients. Adjuvant chemoradiotherapy should be considered in all patients with advanced disease or positive margins who did not receive neo-adjuvant radiotherapy. For metastatic disease, the goal is to prolong and maximize quality of life. Regarding the palliative treatment of dysphagia, brachytherapy was shown to be more effective than stenting.

Oesophageal cancer

2016 ◽  
pp. 365-387
Author(s):  
Melissa Thomas ◽  
Karin Haustermans ◽  
Eric Van Cutsem ◽  
Piet Dirix ◽  
Xavier Sagaert ◽  
...  
Keyword(s):  
Oesophageal Cancer ◽  
Adjuvant Radiotherapy ◽  
Palliative Treatment ◽  
Early Stage ◽  
Locally Advanced ◽  
Adjuvant Chemoradiotherapy ◽  
Valuable Alternative ◽  
Early Stage Carcinoma

Worldwide, oesophageal cancer, including cancer of the gastro-oesophageal junction (GEJ), is the sixth leading cause of death from cancer. Despite recent advances, treatment of oesophageal cancer remains challenging and is best approached by an experienced multidisciplinary team. Surgery alone is the treatment of choice in early stage carcinoma although in superficial cancers (T1a) endoscopic resection is to be preferred. In locally advanced tumours induction therapy followed by surgery is the preferred treatment. In selected cases definitive chemoradiotherapy could be considered as a valuable alternative. The role of adjuvant chemotherapy is unclear, but could be considered for selected GEJ adenocarcinoma patients. Adjuvant chemoradiotherapy should be considered in all patients with advanced disease or positive margins who did not receive neo-adjuvant radiotherapy. For metastatic disease, the goal is to prolong and maximize quality of life. Regarding the palliative treatment of dysphagia, brachytherapy was shown to be more effective than stenting.

Oesophageal cancer

2016 ◽  
pp. 365-387
Author(s):  
Piet Dirix ◽  
Reinhilde Weytjens ◽  
Sabine Vanderkam ◽  
Karin Haustermans ◽  
Eric Van Cutsem ◽  
...  
Keyword(s):  
Oesophageal Cancer ◽  
Palliative Treatment ◽  
Early Stage ◽  
Locally Advanced ◽  
Adjuvant Chemoradiotherapy ◽  
Locally Advanced Tumors ◽  
Early Stage Carcinoma ◽  
Advanced Tumors

Worldwide, oesophageal cancer, including cancer of the gastro-oesophageal junction (GEJ), is the sixth leading cause of death from cancer. Despite recent advances, treatment of oesophageal cancer remains challenging and is best approached by an experienced multidisciplinary team. Surgery alone is the treatment of choice in early stage carcinoma although in superficial cancers (T1a) endoscopic resection is to be preferred. In locally advanced tumors induction therapy followed by surgery is the preferred treatment. In selected cases definitive chemoradiotherapy could be considered as a valuable alternative The role of adjuvant chemotherapy is unclear, but could be considered for selected GEJ adenocarcinoma patients. Adjuvant chemoradiotherapy should be considered in all patients with advanced disease or positive margins who did not receive neo-adjuvant radiotherapy. For metastatic disease, the goal is to prolong and maximize quality of life. Regarding the palliative treatment of dysphagia, brachytherapy was shown to be more effective than stenting.

Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer

2015 ◽  
Vol 10 (2) ◽  
pp. 101-110 ◽  
Author(s):  
Matias E. Valsecchi ◽  
Gerrit Kimmey ◽  
Arvinder Bir ◽  
Damian Silbermins
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Early Stage ◽  
Early Stage Breast Cancer

scholarly journals The Ability of Metabolomics to Discriminate Non-Small-Cell Lung Cancer Subtypes Depends on the Stage of the Disease and the Type of Material Studied

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3314
Author(s):  
Tomasz Kowalczyk ◽  
Joanna Kisluk ◽  
Karolina Pietrowska ◽  
Joanna Godzien ◽  
Miroslaw Kozlowski ◽  
...  
Keyword(s):  
Metabolic Pathways ◽  
Early Stage ◽  
Chronic Obstructive ◽  
Liquid Chromatography Mass Spectrometry ◽  
Obstructive Pulmonary Disease ◽  
Cell Lung Carcinoma ◽  
Cancer Subtypes ◽  
Inflammatory State ◽  
Nsclc Patients

Identification of the NSCLC subtype at an early stage is still quite sophisticated. Metabolomics analysis of tissue and plasma of NSCLC patients may indicate new, and yet unknown, metabolic pathways active in the NSCLC. Our research characterized the metabolomics profile of tissue and plasma of patients with early and advanced NSCLC stage. Samples were subjected to thorough metabolomics analyses using liquid chromatography-mass spectrometry (LC-MS) technique. Tissue and/or plasma samples from 137 NSCLC patients were analyzed. Based on the early stage tissue analysis, more than 200 metabolites differentiating adenocarcinoma (ADC) and squamous cell lung carcinoma (SCC) subtypes as well as normal tissue, were identified. Most of the identified metabolites were amino acids, fatty acids, carnitines, lysoglycerophospholipids, sphingomyelins, plasmalogens and glycerophospholipids. Moreover, metabolites related to N-acyl ethanolamine (NAE) biosynthesis, namely glycerophospho (N-acyl) ethanolamines (GP-NAE), which discriminated early-stage SCC from ADC, have also been identified. On the other hand, the analysis of plasma of chronic obstructive pulmonary disease (COPD) and NSCLC patients allowed exclusion of the metabolites related to the inflammatory state in lungs and the identification of compounds (lysoglycerophospholipids, glycerophospholipids and sphingomyelins) truly characteristic to cancer. Our results, among already known, showed novel, thus far not described, metabolites discriminating NSCLC subtypes, especially in the early stage of cancer. Moreover, the presented results also indicated the activity of new metabolic pathways in NSCLC. Further investigations on the role of NAE biosynthesis pathways in the early stage of NSCLC may reveal new prognostic and diagnostic targets.

Sign in / Sign up

Export Citation Format

Share Document